ACEA Biosciences – A Part of Agilent Launches the xCELLigence RTCA ePacer to improve the Quality and Functionality of hiPSC-Cardiomyocytes for Drug Discovery, Safety Pharmacology, and Cardiac Disease Research

SAN DIEGO–(BUSINESS WIRE)–On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacerTM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) are increasingly being used as a human-relevant in vitro model system for drug discovery, safety pharmacology, and cardiac disease research. While these cells are “fit for purpose” for a number of applications, their i

Click to view original post

Advertise With Us